Prophylaxis of CVB3-induced Myocarditis by Intranasal Immunization with Chitosan-pcDNA3-VP1 Vaccine

徐薇,张进平,陈瑞珍,熊思东

DOI: https://doi.org/10.3969/j.issn.1001-2478.2004.02.017

2004-01-01

Abstract:To see if chitosan-DNA vaccine could effectively prevent development of CVB3-induced myocarditis, chitosan-pcDNA3-VP1 vaccine were prepared by complexing chitosan with pcDNA3-VP1 DNA and administrated to BALB/c mice intranasally with 200 μg DNA at 7 days intervals, 50 μg DNA each time. Mice were infected with 3×LD 50 CVB3 3 weeks later. Loss of body weight, body/heart weight ratio and HE staining of heart tissues was observed and compared. The experimental results showed that: Intranasal delivery of chitosan-pcDNA3-VP1 successfully induced high levels of serum IgG and mucosal IgA; meanwhile activated CVB3-specific CTL activities. 7 days following 3×LD 50 CVB3 infection, HE staining of myocardial tissues showed that only 1/6 of incidence and very light myocarditis were seen in chitosan-pcDNA3-VP1 immunized mice, while in pcDNA3 and chitosan-pcDNA3 immunized mice 6/6 incidence and extremely severe myocarditis were observed. Chitosan-pcDNA3-VP1 immunized mice increased their body weight by 1.75% just as normal mice, while other groups lost their weight. The body/heart weight ratio of pcDNA3 group was as low as 171.75, while that of chitosan-DNA group reached 186.36 suggesting light myocarditis. Data totally show that novel chitosan-pcDNA3-VP1 vaccine could generate CVB3-specific systemic and mucosal immunity, therefore significantly prevent the development of CVB3-induced myocarditis and has the possibility to be a novel prophylactic CVB3 vaccine in the future.